Use of VEGF-C to prevent restenosis

Details Use of VEGF-C to prevent restenosis Use of VEGF-C to prevent restenosis

2005-10-25

2005-10-25

Fredman, Jeffrey (Department: 1636)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S093210, C435S069100, C435S320100, C435S325000, C435S455000, C514S04400A, C536S023100, C536S023500

Reexamination Certificate

active

06958147

ABSTRACT:
The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.

REFERENCES:
patent: 5087244 (1992-02-01), Wolinsky et al.
patent: 5631237 (1997-05-01), Dzau et al.
patent: 5652225 (1997-07-01), Isner
patent: 5653689 (1997-08-01), Buelna et al.
patent: 5674192 (1997-10-01), Sahatjian et al.
patent: 5679400 (1997-10-01), Tuch
patent: 5697967 (1997-12-01), Dinh et al.
patent: 5700286 (1997-12-01), Tartaglia et al.
patent: 5707385 (1998-01-01), Williams
patent: 5713860 (1998-02-01), Kaplan et al.
patent: 5749848 (1998-05-01), Jang et al.
patent: 5776184 (1998-07-01), Tuch
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5779729 (1998-07-01), Severini
patent: 5785965 (1998-07-01), Pratt et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5795898 (1998-08-01), Brown et al.
patent: 5799384 (1998-09-01), Schwartz et al.
patent: 5800507 (1998-09-01), Schwartz
patent: 5824048 (1998-10-01), Tuch
patent: 5830879 (1998-11-01), Isner
patent: 5924048 (1999-07-01), McCormack et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 5994300 (1999-11-01), Bayne et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6121246 (2000-09-01), Isner
patent: 95/24473 (1995-09-01), None
patent: 96/24473 (1995-09-01), None
patent: 96/39515 (1996-12-01), None
patent: 97/05250 (1997-02-01), None
patent: 97/09427 (1997-03-01), None
patent: 97/17359 (1997-05-01), None
patent: 97/17442 (1997-05-01), None
patent: WO 98/07832 (1998-02-01), None
patent: 98/07832 (1998-02-01), None
patent: 98/19712 (1998-05-01), None
patent: 98/20027 (1998-05-01), None
patent: 98/24811 (1998-06-01), None
patent: 98/33917 (1998-08-01), None
patent: 98/49300 (1998-11-01), None
patent: 99/07844 (1999-02-01), None
patent: 99/46364 (1999-09-01), None
Rosenberg et al, Gene Therapist, Heal Thyself. Science 287:1751, 2000.
Verma, Gene Therapy: beyond 2000. Mol. Ther.. 1:493, 2000.
Friedmann, Principles for Human Gene Therapy Studies. Science 287(5461):2163-5, 2000.
Anderson WF, Human Gene Therapy. Nature 392:25-30, 1998.
Hiltunen et al Circulation 102:2262-2268, 2000.
Touchette, Gene Therapy: Not ready for prime time. Nat. Med. 2(1) 7-8, 1996.
DeYong et al Gene Therapy for Restenosis. Circ Res. 82:306-313, 1998.
Ngo, Computational complexity Protein structure prediction and the Levinthal paradox in The Protein Folding Problem and Tertiary Structure Prediction, Merz et al. (eds.), Birkhauser Boston: Boston, MA, pp. 433 and 492-495, 1994).
Rudinger Characteristics of amino acids as components of a peptide hormone sequence (in Peptide Hormones, Parsons (ed.), University Park Press: Baltimore, MD, pp. 1-7, 1976).
Eck et al., “Gene-based therapy.” Goodman & Gilman's The Pharmacological Basis of Therapeutics- Ninth Edition, McGraw-Hill: 77-101, 1996.
Turunen et al., Exp. Gerontol., vol. 34 (4): 567-574, 1999.
Laitinen et al., Pharmacol. Res., vol. 37 (4): 251-254, 1998.
Enholm et al., Trends in Cardiovascular Medicine, vol. 8 (7): 292-297, 1998.
Joukov et al., EMBO J., vol. 15 (2): 290-298, 1996.
Crystal R., “Transfer of genes to humans: Early lessons and obstacles to success.” Science, vol. 270: 404-410, 1995.
Witzenbichler et al., American Journal of Pathology, vol. 153 (2): 381-94, Aug. 1998.
Verma et al., “Gene therapy-promises, problems and prospects.” Nature, vol. 389: 239-242, Sep. 1997.
Deonarain M., “Ligand-targeted receptor-mediated vectors for gene delivery.” Exp. Opin. Ther. Patents, vol. 8 (1): 53-69, 1998.
Miller et al., “Targeted vectors for gene therapy.” FASEB, vol. 9:190-199, Feb. 1995.
Achen, M.G. et al., “Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4),”Proc. Natl. Acad. Sci. USA95(2):548-553 (Jan., 1998).
Alitalo et al., “Vascular Endothelial Growth Factors B and C and Receptors Involved in Angiogenesis,”German-American Academic Council Foundation(GAAC)/ Stiftung Deutsch-Amerikanisches Akademisches Konzil(DAAK),2nd Symposium on Current Problems in Molecular Medicine: The Role of Cytokines in Human Disease,Nov. 17-20, 1996, Ringberg Castle, Germany, p. 1 (Abstract).
Asahara, et al., “Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165gene transfer,”Circulation94:3291-3302 (1996).
Asahara, et al., “Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery,”Circulation91:2793-2801 (1995).
Barr, et al., “Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus,”Gene Ther.1:51-58 (1994).
Boshart, et al., “A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus,”Cell41:521-530 (Jun., 1985).
Callow, et al., “Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty,”Growth Factors10:223-228 (1994).
Camenzind et al., “Use of Locally Delivered Conventional Drug Therapies,”Semin Intervent Cardiol1:67-76 (1996).
Cao, et al., “Vascular endothelial growth factor-C induces angiogenesis in vivo,”Proc. Natl. Acad. Sci.95:14389-14394 (1998).
Cerek, et al., “Growth factors in pathogenesis of coronary arterial restenosis,”Am. J. Cardiol.,68:24C-33C (Nov., 1991).
Chang, et al., “Gene therapy for vascular proliferative disorders,”Semin. Intervent. Cardiol.1:185-193 (1996).
Darius, et al., “Lokale Medikamentengabe und Gentherapie,”Herz22:347-54 (1997).
Davis, et al., “Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression,”Hum. Gene Ther.4:151-9 (1993).
Debbas, et al., “Stenting within a stent: Treatment for repeat in-stent restenosisin a venous graft,”American Heart Journal133:460-468 (Apr., 1997).
De Meyer, et al., “Mechanisms of neointima formation-lessons from experimental models,”Vasc. Med.2:179-189 (1997).
DeYoung, et al., “Gene therapy for restenosis: Are we ready?,”Circ. Res.82:306-313 (1998).
Dignam, et al., “Balbiani ring 3 in Chironomus tentans encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar,”Gene88:133-140 (1990).
Enholm, et al., “Vascular endothelial growth factor-C, a growth factor for lymphatic endothelial cells,”Trends in Cardiovascular Med.8:292-297 (1998).
Enholm, et al., “Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia,”Oncogene14:2475-2483 (1997).
Feldman, et al., “Perspectives of arterial gene therapy for the prevention of restenosis,”Cardiovascular Research32:194-207 (1996).
Ferrara, et al., “Clinical applications of angiogenic growth factors and their inhibitors,”Nature Med 5:1359-64 (Dec. 1999).
GenBank Accession No. AJ000185Homo sapiensmRNA for vascular endothelial growth factor-D.
GenBank Accession No. AF014827Rattus norvegicusvascular endothelial growth factor-D (VEGF-D) mRNA, complete cds.
GenBank Accession No. MMU73620Mus musculusVEGF-C mRNA, complete cds.
GenBank Accession No. CCY15837 Coturnix coturnix mRNA for vascular endothelial growth factor C.
GenBank Accession No. D89628Mus musculusmRNA for vascular endothelial growth factor D, complete cds.
GenBank Accession No. X94216H. sapiensmRNA for VEGF-C protein.
Gnatenko, et al., “Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells,”J. Investig. Med.45:87-89 (1997).
Grosskreutz, et al., “Vascular endothelial growth-factor-induced migration of vascular smooth muscle cells in vitro,”Mi

Affiliated with

Also associated with

Rating

Use of VEGF-C to prevent restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of VEGF-C to prevent restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of VEGF-C to prevent restenosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3445628